BOULDER, Colo., Aug. 28, 2018 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the appointment of Marvin H. Caruthers, Ph.D., to its board of directors.
"I'm pleased to welcome Dr. Caruthers to the ArcherDX Board of Directors," Dr. Jason Myers, CEO and Co-founder of ArcherDX, said in a statement. "Marv has an outstanding track record of helping to develop leading biotechnology companies and will add significant value to the company as we grow our next-generation sequencing-based business at ArcherDX."
Marvin H. Caruthers, Ph.D., is a Distinguished Professor of Chemistry and Biochemistry at the University of Colorado and a pioneer in the biotechnology field. Dr. Caruthers co-founded several biotech companies, including Amgen, Applied Biosystems, and Array BioPharma. He was recently inducted into the National Inventors Hall of Fame for his groundbreaking research on DNA synthesis techniques that are widely used today. Dr. Caruthers was also awarded the National Medal of Science for 2006, the nation's highest distinction honoring scientific achievement, and is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.
About ArcherDX ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. Learn more at archerdx.com.